A mobile device reducing airborne particulate can improve air quality
Messina G., et al. Presented at EUPHA 2019. A key finding: When the system was turned off intraoperatively, contamination rapidly increased.
Messina G., et al. Presented at EUPHA 2019. A key finding: When the system was turned off intraoperatively, contamination rapidly increased.
Messina G., et al. Presented at EUPHA 2019. During mobile device operation, the amount of particulate matter remains significantly lower, reducing the probability of SSI.
Russell Nassof, JD; Kathy Warye, Maureen Spencer, MEd, RN, CIC, FAPIC. Infection Control Today, September 2018. While there is a host of factors in OR environment and practice that can contribute to SSI, there is a growing body of evidence which suggests that air quality merits heightened attention on the part of the infection prevention community.
Cook, T., DO, Piatt, C., DO, Barnes, S. BSN, Edmiston, Jr., C.E. PhD. The Journal of Arthroplasty, 2018. While PJI is multifactorial in nature, this study suggests the use of intraoperative supplemental air decontamination significantly reduced the overall risk of PJI.
Werner Bischoff, MD PhD, FSHEA, Gregory Russell MS, Elisabeth Willard AAS, John Stehle Jr PhD. American Journal of Infection Control, 2019. Aerosol transmission of pathogens can result in the rapid spread of disease. The mobile air recirculation system significantly decreased the bacterial load by over 40%.
Jason leads our global sales team and brings over 18 years of Medical Device experience to Aerobiotix. Jason has led top performing National and Regional Sales teams, selling disruptive technology in the Cardiovascular space with Getinge, Surgical Robotics at Hansen Medical and most recently in the Biologics space with Axogen. Jason received his Bachelor of Science Degree from the University of Indianapolis.
Melissa Gietzen, MBA is a highly skilled strategic marketing professional with over 20 years’ experience in the healthcare industry. She has significant expertise in strategic planning, capital budgeting, service improvement projects, and creating strong successful brands in the orthopedic, cardiac & ophthalmology markets. Melissa holds a undergraduate degree in Management and Organization Development and a masters degree in Business Administration.
The founder and CEO is David Kirschman, M.D., a former physician with extensive experience as CEO, Director, Chief Scientific Officer and operator in the orthopedic and biologic medical device space. Dr. Kirschman holds 55 issued US Patents for a wide range of medical devices. He received his BS in Biological Science cum laude from Colorado State University and M.D. from University of Colorado School of Medicine.
Dr. Carroll has extensive experience in ultraviolet and photonic science. Prior to joining Aerobiotix, he led the research and development group at Sunstar Engineering. He has a Ph.D. in chemistry from Columbia University and did his postdoctoral fellowship under Nobel laureate Prof. Ben Feringa at the University of Groningen, Netherlands, and Lawrence Berkeley National Laboratory.
Tony leads our global sales organization and commercialization strategy. Prior joining Aerobiotix, he was Senior Manager of Strategy at Stryker. He has led sales and marketing teams in multiple organizations including SurgiCount Medical, part of Patient Safety Technologies, INC (PSTX) as it expanded from 8 hospitals in 2008 to user base of 330 hospitals at time of acquisition in 2013.
Dr. Adams leads our global clinical research and education initiatives as well as developing key opinion leaders to support our clinical mission. Prior to joining Aerobiotix, she held leading research and medical affairs roles at Biogen, Axogen, and MedPace. Dr. Adams holds Ph.D. in Pharmacology from University of Cincinnati.
Anthony is a topflight medical device product development engineer and leader, experienced in the development and implementation of orthopedic, environmental, and electromechanical systems.
Nathan brings a high level of commitment to servicing and building client relations. Nathan has previously held leadership roles in the medical device industry.
Mr. Schmitz is a highly experienced financial practitioner with financial leadership roles in diverse industries including manufacturing and technology as well as a background in public accounting. He received his BS in accounting, cum laude, from the Miami University of Ohio. Mr. Schmitz is a certified public accountant and certified management accountant.